Drugs / HM95573
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03284502 | May 2017 → Sep 2024 | metastatic neoplasm | Hanmi Pharmaceutical Company Limited | Unknown | No outcome recorded |
| Phase 1 | NCT03118817 | May 2017 → Feb 2020 | neoplasm | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02405065 | Jan 2015 → Jan 2017 | neoplasm | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HM95573 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03118817 ↗ |
| Route | Oral | “after oral administration.” NCT02405065 ↗ |